Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey

Abstract

SSAO/VAP-1 is a promising anti-inflammatory target. Another important field for therapeutic application of these inhibitors may be ophthalmology, due to their antiangiogenic effects. SSAO substrates might also be of therapeutic value in the treatment of diabetes; however, more extensive research has to be undertaken to validate this approach.

Pharmacologic blockade of vascular adhesion protein-1 lessens neurologic dysfunction in rats subjected to subarachnoid hemorrhage

“…The common element in those 3 reports was that neuroprotection could be achieved through treatment with highly selective blockers of vascular adhesion protein-1 (VAP-1). That endothelial protein is thought to play a key role in promoting adhesion and transmigration of polymorphonuclear leukocytes, monocytes, and lymphocytes (e.g., Dunkel et al, 2011;Hernandez-Guillamon et al, 2010;Watcharotayangul et al, 2012).…”

Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia

“…The association of SSAO activity in plasma and in tissues for future vascular outcomes merits further research, as SSAO has been suggested as a therapeutic target, particularly in relationship to its inflammatory and anti-angiogenic effects. 47 …”

Small molecule and peptide therapies for chronic heart failure: a patent review (2011 – 2014)

“…A link between elevated plasma SSAO and mortality in CHF patients suggests that SSAO inhibition could prevent additional vascular damage [119]. A patent review of SSAO inhibitors was published in 2011 [120]. Several companies, led by Proximagen, have disclosed small molecules recently.…”